fashion -WSS

fashion

author：fashion 2025-09-03 03:40:10 - browse：66643

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

WSS

Intellia reports positive results for its CRISPR

With trial win, GSK could get blood cancer drug back on market

Intellia reports positive results for its CRISPR

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Shifting the focus from loneliness to social health

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Hepatitis C has a cure — but many Americans still lack access to it

What health policies could hitch a ride on a spending bill?

Medicare details structure of new drug price negotiation program

Ionis drug prevents swelling attacks due to hereditary angioedema

Cancer drug shortages should be causing more outrage

Weight loss drugs should be covered by insurers, AMA says

Dobbs anniversary: the lost opportunity of abortion as health care

Type 2 diabetes prevention programs work at large scale: study

focus

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Cancer diagnosis changes perspective doctor, former hospital CEO

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Experimental asthma app from Apple and Anthem shows promise

explore

explore

hotspot

leisure time